TVTX

Travere Therapeutics Inc

TVTX, USA

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

https://www.travere.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
TVTX
stock
TVTX

Travere Therapeutics (NASDAQ: TVTX) issues 20,300 new-hire RSUs vesting over four years Stock Titan

Read more →
TVTX
stock
TVTX

Prepare Yourself for Liftoff: Travere Therapeutics Inc (TVTX) Setenews

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$41.5

Analyst Picks

Strong Buy

11

Buy

2

Hold

2

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

48.59

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

34.94 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Low

4.77 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Low

8.60 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

6.32

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 99.54% of the total shares of Travere Therapeutics Inc

1.

HHG PLC

(10.7039%)

since

2025/06/30

2.

Armistice Capital, LLC

(9.9575%)

since

2025/06/30

3.

BlackRock Inc

(9.1643%)

since

2025/06/30

4.

Vanguard Group Inc

(6.7247%)

since

2025/06/30

5.

Macquarie Group Ltd

(5.7186%)

since

2025/06/30

6.

State Street Corp

(3.9076%)

since

2025/06/30

7.

Macquarie Small Cap Core I

(3.7708%)

since

2025/07/31

8.

Vanguard Total Stock Mkt Idx Inv

(3.1283%)

since

2025/07/31

9.

Adage Capital Partners Gp LLC

(3.1232%)

since

2025/06/30

10.

Renaissance Technologies Corp

(2.7991%)

since

2025/06/30

11.

iShares Russell 2000 ETF

(2.3855%)

since

2025/08/31

12.

Emerald Advisers, LLC

(2.3462%)

since

2025/06/30

13.

Geode Capital Management, LLC

(2.2478%)

since

2025/06/30

14.

Rock Springs Capital Management LP

(2.1407%)

since

2025/06/30

15.

Janus Henderson Global Life Sciences D

(1.9767%)

since

2025/06/30

16.

Janus Henderson Global Life Sciences

(1.9767%)

since

2025/06/30

17.

Bank of America Corp

(1.819%)

since

2025/06/30

18.

Morgan Stanley - Brokerage Accounts

(1.7597%)

since

2025/06/30

19.

Goldman Sachs Group Inc

(1.7466%)

since

2025/06/30

20.

Kynam Capital Management, LP

(1.7284%)

since

2025/06/30

21.

SPDR® S&P Biotech ETF

(1.6927%)

since

2025/08/31

22.

Janus Henderson Glb Life Scn I2 USD

(1.6874%)

since

2025/07/31

23.

Janus Global Life Science AUSD

(1.6321%)

since

2025/06/30

24.

Eversept Partners, LLC

(1.4753%)

since

2025/06/30

25.

Nuveen, LLC

(1.3399%)

since

2025/06/30

26.

RA Capital Management, LLC

(1.2901%)

since

2025/06/30

27.

Emerald Mutual Fund Advisers Trust

(1.2805%)

since

2025/06/30

28.

D. E. Shaw & Co LP

(1.2685%)

since

2025/06/30

29.

HBM Healthcare Investments AG Ord

(1.1975%)

since

2025/06/30

30.

Fidelity Small Cap Index

(0.9902%)

since

2025/06/30

31.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9557%)

since

2025/07/31

32.

iShares Russell 2000 Growth ETF

(0.8141%)

since

2025/08/31

33.

abrdn Healthcare Investors

(0.6971%)

since

2025/08/31

34.

Nuveen Quant Small Cap Equity R6

(0.6647%)

since

2025/07/31

35.

Janus Henderson Hrzn Biotec E2 USD

(0.6502%)

since

2025/06/30

36.

iShares Biotechnology ETF

(0.5876%)

since

2025/08/31

37.

Candriam Eqs L Biotech C USD Cap

(0.5751%)

since

2025/07/31

38.

Macquarie Small Cap Growth C

(0.5462%)

since

2025/07/31

39.

Emerald Growth A

(0.5392%)

since

2025/07/31

40.

Impax US Small Cap Strategy Composite

(0.5329%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

0.59

EPS Estimate

-0.287

EPS Difference

0.877

Surprise Percent

305.5749%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(6)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(7.5)
GARP
Fair GARP(6)
Growth
Moderate Growth(6)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
High Quality(8)
Value
Undervalued(6.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.